Skip to content

Study · Not a test of the peptide alone · 2020

2 results

Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo.

Peng R, Xu C, Zheng H, Lao X

ACS omega27 Apr 2020Cited by 8 (Europe PMC)

PMID32426594 (opens in a new tab)PMCIDPMC7226852 (opens in a new tab)DOI10.1021/acsomega.0c00220 (opens in a new tab)PepBankPUB-32426594
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In H460 and LLC tumor models, the modified peptide Tα1-RGDR had remarkable antitumor effects.

    In plain wordsIn tumor models, the modified peptide Tα1-RGDR had strong antitumor effects.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAntitumor effect of Tα1-RGDR
    Study

    n: not reported in source

    H460 and LLC tumor models
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Tα1-RGDR had remarkable antitumor effects, and its tumor targeting was better than that of Tα1.
    2 context sentences
    Summary · context
    We produced a polypeptide, Tα1-RGDR, by binding Tα1 to RGDR.
    Summary · context
    This work aimed to investigate the difference of antitumor activity and tumor targeting between Tα1 modified by RGDR and Tα1 by using H460 and LLC tumor models.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Activity measurement

    In H460 and LLC tumor models, Tα1-RGDR targeted tumors better than unmodified Tα1.

    In plain wordsIn tumor models, the modified peptide reached tumors better than unmodified thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTumor targeting of Tα1-RGDR compared with Tα1
    Study

    n: not reported in source

    H460 and LLC tumor models
    Comparator
    Tα1
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    its tumor targeting was better than that of Tα1.
    2 context sentences
    Summary · context
    We produced a polypeptide, Tα1-RGDR, by binding Tα1 to RGDR.
    Summary · context
    This work aimed to investigate the difference of antitumor activity and tumor targeting between Tα1 modified by RGDR and Tα1 by using H460 and LLC tumor models.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.